Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

Sickle-cell disease

Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504 · see citing works

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia

Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · see citing works

Fetal hemoglobin in sickle cell anemia

Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553 · see citing works

GBT 440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

Oksenberg, D., Dufu, K., Patel, M. P., Chuang, C.-Y., Li, Z., Xu, Q. R., Silva‐Garcia, A., Zhou, C., Hutchaleelaha, A., Patskovska, L. N., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14214 · Cited by 244 · see citing works

Residue-Specific pKa Determination of Lysine and Arginine Side Chains by Indirect 15N and 13C NMR Spectroscopy: Application to apo Calmodulin

André, I., Linse, S. S., & Mulder, F. A. A. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0721824 · Cited by 119 · see citing works

Determination of the pK values for the alpha-amino groups of human hemoglobin.

Garner, M. H., Bogardt, R. A., & Gurd, F. R. N. (1975) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)41315-x · Cited by 107 · see citing works

Structural Basis for the Potent Antisickling Effect of a Novel Class of Five-Membered Heterocyclic Aldehydic Compounds

Safo, M. K., Abdulmalik, O. Y., Danso-Danquah, R. E., Burnett, J. C., Nokuri, S., Joshi, G. S., Musayev, F. N., Asakura, T., & Abraham, D. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0498001 · Cited by 96 · see citing works

Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin

Abdulmalik, O. Y., Ghatge, M. S., Musayev, F. N., Parikh, A., Chen, Q., Yang, J., Nnamani, I., Danso-Danquah, R. E., Eseonu, D. N., Asakura, T., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911036353 · Cited by 52 · see citing works

Pyridyl Derivatives of Benzaldehyde as Potential Antisickling Agents

Nnamani, I., Joshi, G. S., Danso-Danquah, R. E., Abdulmalik, O. Y., Asakura, T., Abraham, D. J., & Safo, M. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890165 · Cited by 45 · see citing works

EFFECT OF BW12C ON OXYGEN AFFINITY OF HAEMOGLOBIN IN SICKLE-CELL DISEASE

Keidan, A. J., White, R. D., Huehns, E. R., FRANKLIN, I. M., Joy, M., & Stuart, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90941-4 · Cited by 42 · see citing works

Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

Rolan, P. E., Mercer, A., Wootton, R., & Posner, J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04465.x · Cited by 34 · see citing works

Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia

Kato, G. J., Lawrence, M. P., Mendelsohn, L. G., Saiyed, R., Wang, X., Conrey, A. K., Starling, J. M., Grimes, G. J., Taylor, J. G., McKew, J. C., et al. (2013) · Blood · doi:10.1182/blood.v122.21.1009.1009 · Cited by 28 · see citing works

Kinetics of the polymerization of hemoglobin in high and low phosphate buffers.

Adachi, K., & Asakura, T. (1982) · PubMed · Cited by 27 · see citing works

X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin.

Wireko, F., & Abraham, D. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2209 · Cited by 26 · see citing works

Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin

Merrett, M., Stammers, D. K., White, R. D., Wootton, R., & Kneen, G. (1986) · Biochemical Journal · doi:10.1042/bj2390387 · Cited by 23 · see citing works

Structures and Oxygen Affinities of Crystalline Human Hemoglobin C (β6 Glu→Lys) in the R and R2 Quaternary Structures

Shibayama, N., Sugiyama, K., & Park, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266056 · Cited by 17 · see citing works

A High-Throughput Microplate Method for Assessing Aggregation of Deoxygenated Hemoglobin S Heterotetramers in Vitro

He, Z., & Russell, J. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5683 · Cited by 5 · see citing works

Sickle cell disease

Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501 · see citing works

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)

Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,112 · see citing works

Advances in covalent drug discovery

Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · see citing works

A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease

Vichinsky, E. P., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A. M., Hassab, H. M. A., Achebe, M. M., Alkindi, S. S. A., Brown, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 634 · see citing works

Hemoglobin: Structure, Function and Allostery

Ahmed, M. H., Ghatge, M. S., & Safo, M. K. (2020) · Subcellular Biochemistry · doi:10.1007/978-3-030-41769-7_14 · Cited by 317 · see citing works

Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment

Inusa, B. P. D., Hsu, L. L.-Y., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K. A., & Atoyebi, W. (2019) · International Journal of Neonatal Screening · doi:10.3390/ijns5020020 · Cited by 343 · see citing works

Treating sickle cell disease by targeting HbS polymerization

Eaton, W. A., & Bunn, H. F. (2017) · Blood · doi:10.1182/blood-2017-02-765891 · Cited by 255 · see citing works

The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management

Darbari, D. S., Sheehan, V., & Ballas, S. K. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13430 · Cited by 256 · see citing works

A proteome-wide atlas of lysine-reactive chemistry

Abbasov, M. E., Kavanagh, M. E., Ichu, T.-A., Lazear, M. R., Tao, Y., Crowley, V. M., Ende, C. W. A., Hacker, S. M., Ho, J. S., Dix, M. M., et al. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00765-4 · Cited by 242 · see citing works

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 212 · see citing works

Sickle Cell Anemia and Its Phenotypes

Williams, T. N., & Thein, S. L. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021320 · Cited by 151 · see citing works

Sickle Cell Disease: Advances in Treatment

Gardner, R. V. (2018) · Ochsner Journal · doi:10.31486/toj.18.0076 · Cited by 134 · see citing works

Lysine-Targeted Inhibitors and Chemoproteomic Probes

Cuesta, A., & Taunton, J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044805 · Cited by 135 · see citing works

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Howard, J., Hemmaway, C. J., Telfer, P. T., Layton, D. M., Porter, J. B., Awogbade, M., Mant, T., Gretler, D. D., Dufu, K., Hutchaleelaha, A., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868893 · Cited by 115 · see citing works

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

Hutchaleelaha, A., Patel, M. P., Washington, C. B., Siu, V., Allen, E., Oksenberg, D., Gretler, D. D., Mant, T., & Lehrer‐Graiwer, J. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13896 · Cited by 102 · see citing works

Sickle Cell Disease, a Review

Tebbi, C. K. (2022) · Hemato · doi:10.3390/hemato3020024 · Cited by 107 · see citing works

Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood

Hankins, J. S., Estepp, J. H., Hodges, J., Villavicencio, M., Robison, L. L., Weiss, M. J., Kang, G., Schreiber, J. E., Porter, J. S., Kaste, S. C., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27228 · Cited by 87 · see citing works

Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients

Gampe, C. M., & Verma, V. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01177 · Cited by 80 · see citing works

2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases

Chen, P., Tang, G., Zhu, C., Sun, J., Wang, X., Xiang, M., Huang, H., Wang, W., Li, L., Zhang, Z., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11595 · Cited by 84 · see citing works

Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients

Rab, M. A. E., van Oirschot, B. A., Bos, J., Merkx, T. H., van Wesel, A. C. W., Abdulmalik, O. Y., Safo, M. K., Versluijs, B. A., Houwing, M. E., Cnossen, M. H., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25443 · Cited by 78 · see citing works

Cell‐Active, Reversible, and Irreversible Covalent Inhibitors That Selectively Target the Catalytic Lysine of BCR‐ABL Kinase

Chen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203878 · Cited by 75 · see citing works

Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes

Chen, Y., Craven, G. B., Kamber, R. A., Cuesta, A., Zhersh, S., Moroz, Y. S., Bassik, M. C., & Taunton, J. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01281-3 · Cited by 71 · see citing works

New drug approvals for 2019: Synthesis and clinical applications

Yuan, S., Yu, B., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112667 · Cited by 68 · see citing works

Recent progress in covalent warheads for in vivo targeting of endogenous proteins

Shindo, N., & Ojida, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116386 · Cited by 66 · see citing works

Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease

Henry, E. R., Cellmer, T., Dunkelberger, E. B., Metaferia, B., Hofrichter, J., Li, Q., Ostrowski, D., Ghirlando, R., Louis, J. M., Moutereau, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922004117 · Cited by 65 · see citing works

Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease

Xu, G. G., Pagare, P. P., Ghatge, M. S., Safo, R. P., Gazi, A., Chen, Q., David, T. M. S., Alabbas, A. B., Musayev, F. N., Venitz, J., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00553 · Cited by 58 · see citing works

Synthetic Approaches to the New Drugs Approved during 2019

Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Mahapatra, S., Carney, D. W., Lindsey, E. A., DeForest, J. C., France, S. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00208 · Cited by 53 · see citing works

ABPP-CoDEL: Activity-Based Proteome Profiling-Guided Discovery of Tyrosine-Targeting Covalent Inhibitors from DNA-Encoded Libraries

Jiang, L., Liu, S., Jia, X., Gong, Q., Wen, X., Lu, W., Yang, J., Wu, X., Wang, X., Suo, Y., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08852 · Cited by 52 · see citing works

Sickle hemoglobin oxygen affinity‐shifting strategies have unequal cerebrovascular risks

Hebbel, R. P., & Hedlund, B. E. (2017) · American Journal of Hematology · doi:10.1002/ajh.24975 · Cited by 50 · see citing works

Voxelotor: First Approval

Blair, H. A. (2020) · Drugs · doi:10.1007/s40265-020-01262-7 · Cited by 50 · see citing works

PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease

Gopalsamy, A., AULABAUGH, A. E., Barakat, A., Beaumont, K. C., Cabral, S., Canterbury, D. P., Casimiro‐Garcia, A., Chang, J. S., Chen, M. Z., Choi, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01518 · Cited by 45 · see citing works

Large library docking for novel SARS‐CoV ‐2 main protease non‐covalent and covalent inhibitors

Fink, E. A., Bardine, C., Gahbauer, S., Singh, I., Detomasi, T. C., White, K. M., Gu, S., Wan, X., Chen, J. S., Ary, B. E., et al. (2023) · Protein Science · doi:10.1002/pro.4712 · Cited by 43 · see citing works

NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE

Mattè, A., Mazzi, F., Federti, E., Olivieri, O., & Franceschi, L. D. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.002 · Cited by 42 · see citing works

Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors

Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 39 · see citing works

Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action

Patel, D., Huma, Z. E., & Duncan, D. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00805 · Cited by 40 · see citing works

Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation

Zang, R., Barth, A., Wong, H., Mařı́k, J., Shen, J., Lade, J. M., Grove, K. J., Durk, M. R., Parrott, N. J., Rudewicz, P. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00502 · Cited by 37 · see citing works

Revolutionising healing: Gene Editing's breakthrough against sickle cell disease

Dimitrievska, M., Bansal, D., Vitale, M., Strouboulis, J., Miccio, A., Nicolaides, K. H., Hoss, S. E., Shangaris, P., & Jackow, J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101185 · Cited by 39 · see citing works

Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease

Pagare, P. P., Ghatge, M. S., Musayev, F. N., Deshpande, T. M., Chen, Q., Braxton, C. N., Kim, S., Venitz, J., Zhang, Y., Abdulmalik, O. Y., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.015 · Cited by 37 · see citing works

Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor

Glaros, A. K., Razvi, R., Shah, N., & Zaidi, A. U. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211001136 · Cited by 40 · see citing works

Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis

Shah, N., Lipato, T., Alvarez, O. A., Delea, T. E., Lonshteyn, A., Weycker, D. A., Nguyen, A., Beaubrun, A. C., & Agodoa, I. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2031967 · Cited by 39 · see citing works

l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?

Leibovitch, J. N., Tambe, A., Cimpeanu, E., Poplawska, M., Jafri, F. M., Dutta, D., & Lim, S. H. (2022) · Blood Reviews · doi:10.1016/j.blre.2021.100925 · Cited by 36 · see citing works

Signaling mechanisms in red blood cells: A view through the protein phosphorylation and deformability

Cilek, N., Uğurel, E., Goksel, E., & Yalçın, Ö. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.30958 · Cited by 36 · see citing works

Emerging pharmacotherapeutic approaches for the management of sickle cell disease

Torres, L. S., & Conran, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1548610 · Cited by 33 · see citing works

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study

van Dijk, M. J., Rab, M. A. E., van Oirschot, B. A., Bos, J., Derichs, C., Rijneveld, A. W., Cnossen, M. H., Nur, E., Biemond, B. J., Bartels, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011477 · Cited by 35 · see citing works

Covalent hits and where to find them

Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 30 · see citing works

HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity

Blume, S. Y., Garg, A., Martí-Mateos, Y., Midha, A. D., Chew, B. T. L., Lin, B., Yu, C., Dick, R. A., Lee, P. S., Situ, E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.029 · Cited by 29 · see citing works

Design of next-generation covalent inhibitors: Targeting residues beyond cysteine

Jones, L. H. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.10.001 · Cited by 28 · see citing works

Systematic Review of Voxelotor: A First‐in‐Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease

Han, J., Saraf, S. L., & Gordeuk, V. R. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2405 · Cited by 25 · see citing works

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions

Abdulmalik, O. Y., Pagare, P. P., Huang, B., Xu, G. G., Ghatge, M. S., Xu, X., Chen, Q., Anabaraonye, N., Musayev, F. N., Omar, A. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77171-2 · Cited by 25 · see citing works

A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness

Okutachi, S., Manoharan, G. B., Kiriazis, A., Laurini, C., Catillon, M., McCormick, F., Yli‐Kauhaluoma, J. T., & Abankwa, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665673 · Cited by 25 · see citing works

Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation

Deshpande, T. M., Pagare, P. P., Ghatge, M. S., Chen, Q., Musayev, F. N., Venitz, J., Zhang, Y., Abdulmalik, O. Y., & Safo, M. K. (2018) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318009919 · Cited by 24 · see citing works

O-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live Cells

Ling, H., Li, L., Duan, L., Huang, W., Zheng, J., Zhang, S., Li, X., Qiu, X., Zhou, Y., Ma, N., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18006 · Cited by 23 · see citing works

Innovative Treatments for Rare Anemias

Cappellini, M. D., Marcon, A., Fattizzo, B., & Motta, I. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000576 · Cited by 23 · see citing works

The antisickling agent, 5‐hydroxymethyl‐2‐furfural: Other potential pharmacological applications

Pagare, P. P., McGinn, M., Ghatge, M. S., Shekhar, V., Alhashimi, R. T., Pierce, B. D., Abdulmalik, O. Y., Zhang, Y., & Safo, M. K. (2024) · Medicinal Research Reviews · doi:10.1002/med.22062 · Cited by 24 · see citing works

Voxelotor ( GBT 440), a first‐in‐class hemoglobin oxygen‐affinity modulator, has promising and reassuring preclinical and clinical data

Estepp, J. H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25042 · Cited by 22 · see citing works

Voxelotor for the treatment of sickle cell disease

Vissa, M., & Vichinsky, E. P. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1893688 · Cited by 22 · see citing works

Quality-by-Design-Based Development of a Voxelotor Self-Nanoemulsifying Drug-Delivery System with Improved Biopharmaceutical Attributes

Buya, A. B., Terrasi, R., Mbinze, J. K., Muccioli, G. G., Beloqui, A., Memvanga, P. B., & Véronique Préat, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091388 · Cited by 22 · see citing works

Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property

Pagare, P. P., Rastegar, A., Abdulmalik, O. Y., Omar, A. M., Zhang, Y., Fleischman, A. N., & Safo, M. K. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.1994945 · Cited by 22 · see citing works

Lysine-Targeted Covalent Inhibitors of PI3Kδ Synthesis and Screening by In Situ Interaction Upgradation

Yuan, B., Feng, Y., Ma, M., Duan, W., Wu, Y., Liu, J., Zhao, H., Yang, Z., Zhang, S., & Xin, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01284 · Cited by 21 · see citing works

Aminomethyl Salicylaldehydes Lock onto a Surface Lysine by Forming an Extended Intramolecular Hydrogen Bond Network

Weaver, J., Craven, G. B., Tram, L., Chen, H., & Taunton, J. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c04314 · Cited by 20 · see citing works

Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies

Papizan, J. B., Porter, S. N., Sharma, A., & Pruett‐Miller, S. M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200096 · Cited by 19 · see citing works

Development and validation of an oxygen dissociation assay, a screening platform for discovering, and characterizing hemoglobin–oxygen affinity modifiers

Patel, M. P., Siu, V., Silva‐Garcia, A., Xu, Q. R., Li, Z., & Oksenberg, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s157570 · Cited by 20 · see citing works

GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model

Dufu, K., Alt, C., Strutt, S. C., Partridge, J. R., Tang, T., Siu, V., Zou, H. L., Rademacher, P., Williams, A. T., Muller, C. R., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18771 · Cited by 19 · see citing works

Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia

Strader, M. B., Liang, H., Meng, F., Delenko, J., Ostrowski, D. A., Henry, E. R., Shet, A. S., Eaton, W. A., Thein, S. L., & Alayash, A. I. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00130 · Cited by 19 · see citing works

Voxelotor (GBT440) produces interference in measurements of hemoglobin S

Rutherford, N. J., Thoren, K. L., Shajani-Yi, Z., & Colby, J. M. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.032 · Cited by 19 · see citing works

A Tight Contact: The Expanding Application of Salicylaldehydes in Lysine‐Targeting Covalent Drugs

Mason, M., Belvisi, L., Pignataro, L., & Corso, A. D. (2023) · ChemBioChem · doi:10.1002/cbic.202300743 · Cited by 18 · see citing works

Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease

Olubiyi, O. O., Olagunju, M. O., & Strodel, B. (2019) · Molecules · doi:10.3390/molecules24244551 · Cited by 18 · see citing works

Biomimetic Synthesis and Chemical Proteomics Reveal the Mechanism of Action and Functional Targets of Phloroglucinol Meroterpenoids

Bracken, A. K., Gekko, C. E., Suss, N. O., Lueders, E. E., Cui, Q., Fu, Q., Lui, A. C. W., Anderson, E. T., Zhang, S., & Abbasov, M. E. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10741 · Cited by 15 · see citing works

A study of the molecular interactions of hemoglobin with diverse classes of therapeutic agents

Zăgrean-Tuza, C., Igescu, I., Lupan, A., & Silaghi-Dumitrescu, R. L. (2024) · Inorganica Chimica Acta · doi:10.1016/j.ica.2024.122053 · Cited by 17 · see citing works

Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?

Mattè, A., Cappellini, M. D., Iolascon, A., Federti, E., & Franceschi, L. D. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1703947 · Cited by 17 · see citing works

Sickle cell disease in the new era: advances in drug treatment

Lee, M. T., & Ogu, U. O. (2022) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2022.103555 · Cited by 15 · see citing works

Sickle Cell Disease: A Genetic Disorder of Beta-Globin

Cordovil, K. (2018) · InTech eBooks · doi:10.5772/intechopen.74778 · Cited by 16 · see citing works

Increased hemoglobin affinity for oxygen with GBT1118 improves hypoxia tolerance in sickle cell mice

Dufu, K., Williams, A. T., Muller, C. R., Walser, C., Lucas, A., Eaker, A. M., Alt, C., Cathers, B. E., Oksenberg, D., & Cabrales, P. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00048.2021 · Cited by 16 · see citing works

Recent advances in “sickle and niche” research - Tribute to Dr. Paul S Frenette -

Torres, L. S., Asada, N., Weiss, M. J., Trumpp, A., Suda, T., Scadden, D. T., & Ito, K. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.06.004 · Cited by 16 · see citing works

Cell‐Active, Reversible, and Irreversible Covalent Inhibitors That Selectively Target the Catalytic Lysine of BCR‐ABL Kinase

Chen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202203878 · Cited by 15 · see citing works

Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias

Pockes, S., Walters, M. A., & Ashe, K. H. (2022) · Translational research · doi:10.1016/j.trsl.2022.10.009 · Cited by 15 · see citing works

Biophysical chemistry behind sickle cell anemia and the mechanism of voxelotor action

Suhail, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-52476-8 · Cited by 16 · see citing works

A review on disease modifying pharmacologic therapies for sickle cell disease

Mahadevia, H. J., Ponvilawan, B., Madan, U., Sharma, P., Qasim, H., & Shrestha, A. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06216-1 · Cited by 16 · see citing works

Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic

Alsayegh, F., & Mousa, S. A. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620955240 · Cited by 16 · see citing works

Hemoglobin Variants as Targets for Stabilizing Drugs

Žoldáková, M., Novotný, M., Khakurel, K. P., & Žoldák, G. (2025) · Molecules · doi:10.3390/molecules30020385 · Cited by 14 · see citing works

Exploration of Structure–Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents

Pagare, P. P., Ghatge, M. S., Chen, Q., Musayev, F. N., Venitz, J., Abdulmalik, O. Y., Zhang, Y., & Safo, M. K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01287 · Cited by 14 · see citing works

Gene Therapy for Hemoglobinopathies

Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 14 · see citing works

Achieving High Affinity for a Bacterial Lectin with Reversible Covalent Ligands

Antonini, G., Bernardi, A., Gillon, É., Corso, A. D., Civera, M., Belvisi, L., Varrot, A., & Mazzotta, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01876 · Cited by 13 · see citing works

Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes

Rutherford-Parker, N. J., Campbell, S., Colby, J. M., & Shajani-Yi, Z. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa067 · Cited by 13 · see citing works

Small molecule modulation of protein polymerization

Fischer, E. S., & Jones, L. H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00070a · Cited by 12 · see citing works

Caspase-2 Inhibitor Blocks Tau Truncation and Restores Excitatory Neurotransmission in Neurons Modeling FTDP-17 Tauopathy

Singh, G., Liu, P., Yao, K. R., Strasser, J. M., Hlynialuk, C. J. W., Leinonen-Wright, K., Teravskis, P. J., Choquette, J. M., Ikramuddin, J., Bresinsky, M., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00100 · Cited by 12 · see citing works

The effect of the antisickling compound GBT 1118 on the permeability of red blood cells from patients with sickle cell anemia

Balushi, H. W. M. A., Dufu, K., Rees, D. C., Brewin, J. N., Hannemann, A., Oksenberg, D., Lu, D. C. ‐., & Gibson, J. S. (2019) · Physiological Reports · doi:10.14814/phy2.14027 · Cited by 12 · see citing works

Advanced technologies for screening and identifying covalent inhibitors

Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 11 · see citing works

MWC allosteric model explains unusual hemoglobin-oxygen binding curves from sickle cell drug binding

Henry, E. R., Delenko, J., Glass, K. E., Metaferia, B. B., Louis, J. M., & Eaton, W. A. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.04.024 · Cited by 11 · see citing works

A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives

Gu, J., Wu, Q., Zhang, Q., You, Q., & Wang, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114742 · Cited by 11 · see citing works

The Evolving Landscape of Drug Therapies for Sickle Cell Disease

Rai, P., Desai, P. C., & Ataga, K. I. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.06.008 · Cited by 11 · see citing works

Identification of human in vitro metabolites of the haemoglobin S polymerization inhibitor voxelotor for doping control purposes

Rzeppa, S., Voss, S. C., Thieme, D., & Keiler, A. M. (2023) · Drug Testing and Analysis · doi:10.1002/dta.3489 · Cited by 11 · see citing works

MEK1/2 as a Therapeutic Target in Sickle Cell Disease

Zennadi, R. (2019) · International Journal of Blood Research and Disorders · doi:10.23937/2469-5696/1410038 · Cited by 10 · see citing works

Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities

Alramadhani, D., Aljahdali, A. S., Abdulmalik, O. Y., Pierce, B. D., & Safo, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137448 · Cited by 10 · see citing works

The thermodynamics of neurodegenerative disease

Meisl, G. (2024) · Biophysics Reviews · doi:10.1063/5.0180899 · Cited by 10 · see citing works

GBT1118, a compound that increases the oxygen affinity of hemoglobin, improves survival in murine hypoxic acute lung injury

Putz, N. D., Shaver, C. M., Dufu, K., Li, C.-M., Xu, Q. R., Hutchaleelaha, A., Lehrer‐Graiwer, J., Majka, S. M., Ware, L. B., & Bastarache, J. A. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00079.2017 · Cited by 10 · see citing works

An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling

Omar, A. M., Abdulmalik, O. Y., Ghatge, M. S., Muhammad, Y. A., Paredes, S. D., El‐Araby, M. E., & Safo, M. K. (2020) · Biomolecules · doi:10.3390/biom10111508 · Cited by 10 · see citing works

Advances in Sickle Cell Disease Management

Engel, E. R., Howard, A., Ankus, E. J., & Rico, J. F. (2020) · Advances in Pediatrics · doi:10.1016/j.yapd.2020.03.001 · Cited by 10 · see citing works

Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease

Alhashimi, R. T., Ghatge, M. S., Donkor, A. K., Deshpande, T. M., Anabaraonye, N., Alramadhani, D., Danso-Danquah, R. E., Huang, B., Zhang, Y., Musayev, F. N., et al. (2022) · Biomolecules · doi:10.3390/biom12050696 · Cited by 9 · see citing works

Voxelotor treatment of a patient with sickle cell disease and very severe anemia

Shet, A. S., Mendelsohn, L. G., Harper, J., Ostrowski, D., Henry, E. R., Gwaabe, E., Nichols, J., Alayash, A. I., Eaton, W. A., & Thein, S. L. (2018) · American Journal of Hematology · doi:10.1002/ajh.25389 · Cited by 9 · see citing works

GBT 440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

Oksenberg, D., Dufu, K., Patel, M. P., Chuang, C.-Y., Li, Z., Xu, Q. R., Silva‐Garcia, A., Zhou, C., Hutchaleelaha, A., Patskovska, L. N., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14214 · Cited by 244 · see citing works

GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species

Hutchaleelaha, A., Patel, M. P., Silva, A., Oksenberg, D., & Metcalf, B. (2015) · Blood · doi:10.1182/blood.v126.23.2172.2172 · Cited by 10 · see citing works

Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia

Strader, M. B., Liang, H., Meng, F., Delenko, J., Ostrowski, D. A., Henry, E. R., Shet, A. S., Eaton, W. A., Thein, S. L., & Alayash, A. I. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00130 · Cited by 19 · see citing works

Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects

Rademacher, P. M., Hutchaleelaha, A., Washington, C. B., Lehrer, J., & Ramos, E. L. (2016) · Blood · doi:10.1182/blood.v128.22.2487.2487 · Cited by 11 · see citing works

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Lehrer‐Graiwer, J., Howard, J., Hemmaway, C. J., Awogbade, M., Telfer, P. T., Layton, M., Mant, T., Dufu, K., Hutchaleelaha, A., Koller, T. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.542.542 · Cited by 29 · see citing works